<DOC>
	<DOCNO>NCT01920204</DOCNO>
	<brief_summary>Rationale : Patients indolent smolder systemic mastocytosis severe disabling symptom . Almost patient fatigue , compromise quality life , hamper normal functioning . Because form mastocytosis consider life-threatening , mast cell eradication never apply patient receive symptomatic therapy histamine blocker . Midostaurin , c-KIT inhibitor show activity regard symptom control decrease malignant mast cell patient aggressive systemic mastocytosis ( ASM ) mast cell leukemia</brief_summary>
	<brief_title>Midostaurin Indolent Systemic Mastocytosis</brief_title>
	<detailed_description>Objective : Primary : To study pilot phase II trial efficacy midostaurin administer oral dose 100 mg twice daily patient indolent smolder systemic mastocytosis mediator symptom reduction , document Mastocytosis Symptom Assessment Questionnaire , measure 3 month . Secondary : 1 . To study whether symptom improvement persist 6 month , whether midostaurin reduce mast cell infiltration skin bone marrow , document decrease serum tryptase , decrease urticaria pigmentosa decrease bone marrow mast cell . 2 . To assess safety tolerability midostaurin mention setting Study design : Single arm , open label pilot phase II study . Study population : Adult patient ( n=20 ) histologically document systemic mastocytosis , indolent smolder subtype , severe symptom , control histamine 1 2 blocker . Intervention : treatment Midostaurin , twice daily 100 mg orally 6 month continuously .</detailed_description>
	<mesh_term>Mastocytosis</mesh_term>
	<mesh_term>Mastocytosis , Systemic</mesh_term>
	<mesh_term>4'-N-benzoylstaurosporine</mesh_term>
	<mesh_term>Staurosporine</mesh_term>
	<criteria>Patients Indolent Systemic Mastocytosis ( ISM ) Smouldering Systemic Mastocytosis ( SSM ) accord WHO criteria Presence D816V cKIT mutation Serum tryptase &gt; 20 mg/l Serious mediatorrelated symptom control H1 H2 block drug . Symptoms score adapted MSAF ( mastocytosis symptom assessment form ) least : prestudy score 4 3 nonrelated item , prestudy score 5 2 nonrelated item . one item score list replace flush 7 per week anaphylactic attack 1 per week . Age &gt; 18 year Willingness apply optimal contraceptive measure ( double barrier method , men woman ) woman age 55 , men age ; : sexually active . Written inform consent Aggressive systemic mastocytosis , mast cell leukemia , ASM without accompany nonclonal relate nonmast cell disorder ( SMANHMD ) . Any known present malignancy , nonmelanoma skin cancer exclude History malignancy within last 5 year , nonmelanoma skin cancer exclude Any serious comorbidity interfere therapy compliance followup compliance Pregnancy Patients willing able comply contraceptive measure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Mastocytosis</keyword>
	<keyword>ISM</keyword>
	<keyword>SSM</keyword>
</DOC>